Moderna Shares Double After Successful Melanoma Vaccine Trial Results
Product·3 articles across 3 outlets·↩ Updated
Story updated Rewritten when the story materially grows; the wire is checked every 15 minutesAbout this data
Moderna and Merck's personalized mRNA vaccine has shown promising results in a late-stage trial, significantly reducing the recurrence of melanoma. The trial involved over 1,100 patients and combined the vaccine with Merck's Keytruda, leading to a 131% surge in Moderna's stock price.
The positive outcome of the trial has revived hopes for mRNA technology in cancer treatment, with Moderna's shares doubling as investors reacted to the news. This breakthrough has implications for the future of melanoma treatment and the broader application of mRNA vaccines in oncology.
ModernaMerck
Sources
Every quote below is verbatim from the article it is attributed to.
SourceReports the news
“Drugmaker’s melanoma shot developed with Merck delivers positive outcome in late-stage trial”
FT — Moderna shares double on skin cancer vaccine success“A personalized vaccine developed by Moderna Inc.”
Bloomberg — Moderna and Merck Revive mRNA Hopes With Melanoma Success“The shot, paired with Merck's Keytruda, cut the risk of melanoma recurrence in a trial of more than 1,100 patients.”
Fortune — Moderna’s and Merck’s personalized mRNA vaccine shows real promise against deadly skin cancer melanoma in late stage trial and sends stocks soaring“A Phase 3 win against the standard of care sent the biotech's shares up 131% and left short sellers down $4.8 billion.”
decrypt — Moderna Stock Doubles on Cancer Breakthrough: Here’s What It Means
SupportCorroborates it
“mRNA cancer vaccine succeeded in Phase 3 melanoma trial, Moderna and Merck say”
Ars Technica — mRNA cancer vaccine succeeded in Phase 3 melanoma trial, Moderna and Merck say“Moderna and Merck announced today that their personalized mRNA-based cancer vaccine, combined with Merck’s immunotherapy medication Keytruda, met initial goals in a late-stage trial.”
fast company — Moderna stock price is skyrocketing on mRNA cancer vaccine trial news: Here’s what’s happening“Merck & Co.”
fierce biotech — <a href="/biotech/merck-and-modernas-personalized-cancer-vaccine-slows-recurrence-ph-3-trial" hreflang="en">Merck, Moderna’s personalized cancer vaccine slows recurrence in phase 3, setting up approval push</a>
Earlier versions
- Aug 19, 11:30 AM — Moderna and Merck's mRNA Cancer Vaccine Achieves Success in Late-Stage Melanoma Trial (3/3)
- Aug 19, 12:15 PM — Moderna, Merck Shares Surge After Melanoma Vaccine Study Success (5/5)
- Aug 19, 3:45 PM — Moderna Share Price Doubles After Successful Melanoma Vaccine Trial (5/4)
- Aug 19, 4:58 PM — Moderna Shares Surge 160% on Cancer Vaccine Success, Hitting Short Sellers Hard (5/5)